Tempest Therapeutics Inc. (TPST)
NASDAQ (CM) NASDAQ (CM) Primary Summary
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
Tempest jumps after EMA grants orphan drug status to its liver cancer candidate, amezalpat, based on positive study data.
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up
Tempest aims to explore strategic alternatives for advancing pipeline studies that maximize shareholder value. Stock rises in after-hours trading.
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
Tempest Therapeutics Inc. TPST stock is trading higher on Thursday, with a strong session volume of over 23 million as per data from Benzinga Pro.
Tempest Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 292 | $1,986 | $365 | -$1,621 | -81.62% |
Tempest Therapeutics Inc. (TPST) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tempest Therapeutics Inc. ever had a stock split?
Tempest Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Matthew Angel CEO | NASDAQ (CM) Exchange | 87978U207 CUSIP |
| US Country | 24 Employees | - Last Dividend | 9 Apr 2025 Last Split | 12 Nov 2012 IPO Date |
Overview
Tempest Therapeutics Inc., founded in 2011 and based in South San Francisco, California, operates as a clinical-stage oncology company dedicated to the innovation of novel small molecule therapeutics for cancer treatment. With its roots as a subsidiary of Inception Sciences, Inc., the company has carved out an independent path in the oncology space, focusing on leveraging scientific advancements to address unmet medical needs in cancer therapy. Tempest Therapeutics' approach is characterized by a deep understanding of cancer biology and a commitment to developing targeted therapies that can potentially offer new hope to patients with solid tumors.
Products and Services
- TPST-1495
TPST-1495 stands out as a dual antagonist targeting both EP2 and EP4 receptors of prostaglandin E2, a significant player in tumorigenesis and immune evasion. Currently undergoing a Phase 1 trial, this molecule is being evaluated for its efficacy in treating solid tumors. TPST-1495's dual antagonism presents a novel approach in cancer therapy, aiming to interfere with the tumor microenvironment and immune system interactions that facilitate cancer progression.
- TPST-1120
Anchoring another aspect of Tempest Therapeutics' pipeline is TPST-1120, a selective antagonist of the peroxisome proliferator-activated receptor alpha (PPARα). This targeted therapy is also in a Phase 1 trial for its application in solid tumors. The rationale behind TPST-1120 focuses on the metabolic alterations in cancer cells, specifically aiming to disrupt the lipid metabolism pivotal for tumor growth and survival, thereby presenting a unique target for cancer treatment.
- TREX-1
In the pre-clinical development stage, TREX-1 represents Tempest Therapeutics' pioneering effort to modulate the innate immune response within the tumor microenvironment. TREX-1 is a key cellular enzyme involved in the regulation of innate immunity, and by targeting it, Tempest aims to unveil new therapeutic strategies that could enhance the immune system's ability to fight cancer. This approach underscores the company's commitment to exploring innovative pathways for oncology treatment.
